Five days' treatment with topical mupirocin, applied twice daily, in 36 patients with moderately severe primary and secondary skin infections, resulted in resolution/much improvement of skin lesions in 75.0% of patients and bacterial eradication in 83.9% of cases. Penicillin-resistant and penicillin-sensitive staphylococci were most commonly implicated. No adverse effects were reported in any of the patients treated. Physicians' assessment of cure/improvement was recorded in 91.7% of patients.
WhiteARBealeASBoonRJ: Antibacterial activity of mupirocin. In: Proceedings of the International Symposium on Bactroban. (DobsonRLLeydenJJNobleNC, eds). Amsterdam: Excerpta Medica, 1984; pp 19–36.
2.
CasewellMWHillRLRDuckworth: The effect of mupirocin (pseudomonic acid) on the nasal carriage of Staphylococcus aureus. In: Proceedings of the International Symposium on Bactroban. (DobsonRLLeydenJJNobleNC, eds). Amsterdam: Excerpta Medica, 1984; pp 47–53.
3.
LeydenJJ: Studies on the safety of bactroban ointment: potential for contact allergy, contact irritation, phototoxicity and photo-allergy. In: Proceedings of the International Symposium on Bactroban. (DobsonRLLeydenJJNobleNC, eds). Amsterdam: Excerpta Medica, 1984; pp 68–71.
4.
MellowsG: Pseudomonic acid: its chemistry and metabolism. In: Proceedings of the International Symposium on Bactroban. (DobsonRLLeydenJJNobleNC, eds). Amsterdam: Excerpta Medica, 1984; pp 3.
